scispace - formally typeset
H

Hannelore Maes

Researcher at Katholieke Universiteit Leuven

Publications -  25
Citations -  6913

Hannelore Maes is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Autophagy & Melanoma. The author has an hindex of 17, co-authored 25 publications receiving 6223 citations. Previous affiliations of Hannelore Maes include Catholic University of Leuven.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Tumor Vessel Normalization by Chloroquine Independent of Autophagy

Hannelore Maes, +23 more
- 11 Aug 2014 - 
TL;DR: By normalizing tumor vessel structure and function and increasing perfusion, CQ reduced hypoxia, cancer cell invasion, and metastasis, while improving chemotherapy delivery and response, supporting the use of CQ for anticancer treatment.
Journal ArticleDOI

ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy.

Michael Dewaele, +2 more
- 01 Oct 2010 - 
TL;DR: The role of autophagy in cancer cells responding to ROS-producing agents, which are utilized as a therapeutic modality to kill cancer cells are focused on.
Journal ArticleDOI

Autophagy: shaping the tumor microenvironment and therapeutic response

Hannelore Maes, +3 more
- 01 Jul 2013 - 
TL;DR: New connections that reveal the role of autophagy in shaping tumor-stroma interaction during carcinogenesis and in the context of anticancer treatments are discussed.
Journal ArticleDOI

Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents.

Ciska Verbaanderd, +7 more
- 23 Nov 2017 - 
TL;DR: Preclinical studies support CQ and HCQ use in anti- cancer therapy, especially in combination with conventional anti-cancer treatments since they are able to sensitise tumour cells to a variety of drugs, potentiating the therapeutic activity.